Cargando…
Pemafibrate therapy for non-alcoholic fatty liver disease is more effective in lean patients than obese patients
INTRODUCTION: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world, with an increasing incidence. Pemafibrate is a novel selective peroxisome proliferator-activated receptor-a (PPAR-a) modulator which is expected to improve NAFLD. The aim of this study is t...
Autores principales: | Shinozaki, Satoshi, Tahara, Toshiyuki, Miura, Kouichi, Lefor, Alan Kawarai, Yamamoto, Hironori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9850303/ https://www.ncbi.nlm.nih.gov/pubmed/36683866 http://dx.doi.org/10.5114/ceh.2022.120099 |
Ejemplares similares
-
Effectiveness of One-Year Pemafibrate Therapy on Non-Alcoholic Fatty Liver Disease Refractory to Long-Term Sodium Glucose Cotransporter-2 Inhibitor Therapy: A Pilot Study
por: Shinozaki, Satoshi, et al.
Publicado: (2023) -
Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease
por: Shinozaki, Satoshi, et al.
Publicado: (2020) -
Pemafibrate improves hepatic inflammation, function and fibrosis in patients with non-alcoholic fatty liver disease: a one-year observational study
por: Shinozaki, Satoshi, et al.
Publicado: (2021) -
The Pocket-Creation Method Facilitates Endoscopic Submucosal Dissection of Gastric Neoplasms Along the Lesser Curvature at the Gastric Angle
por: Kitamura, Masafumi, et al.
Publicado: (2022) -
An Ultrathin Endoscope with a 2.4-mm Working Channel Shortens the Esophagogastroduodenoscopy Time by Shortening the Suction Time
por: Shinozaki, Satoshi, et al.
Publicado: (2015)